<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Bill R</dc:creator>
  <dc:creator>Christofori G</dc:creator>
  <dc:date>2016</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">The Rip1Tag2 transgenic mouse model of β-cell carcinogenesis has been instrumental in studying various aspects of tumor angiogenesis and in investigating the response to anti-angiogenic therapeutics. Thereby, the in-depth assessment of blood and lymphatic vessel phenotypes and functionality represents key experimental analyses. In this chapter, we describe basic protocols to assess tumor blood vessel morphology (pericyte coverage), functionality (perfusion, leakiness, and hypoxia), lymphatic tumor coverage, and tumor cell proliferation and apoptosis based on immunofluorescence microscopy analysis.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/90678</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/978-1-4939-3999-2_14</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/27858364</dc:relation>
  <dc:source>Methods in molecular biology (Clifton, N.J.). - 2016</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Anti-angiogenic therapy</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Endothelial cells</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Immunofluorescence</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Insulinoma</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">PNET</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Rip1Tag2</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Tumor angiogenesis</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Animals</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Antigens, Viral, Tumor</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Apoptosis</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Carcinoma, Neuroendocrine</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Cell Proliferation</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Insulin</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Insulinoma</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Mice</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Mice, Transgenic</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Neoplasms, Experimental</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Neovascularization, Pathologic</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Pancreatic Neoplasms</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Promoter Regions, Genetic</dc:subject>
  <dc:title xmlns:ns21="xml" ns21:lang="en">The Rip1Tag2 Transgenic Mouse Model.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>